Emergency Use Authorization for COVID-19 Vaccines and Practical Considerations for the Future
Abstract: An Emergency use authorization (EUA) is a permission granted by the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as revised and upgraded by numerous Federal legislations, which includes the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, accumulated by 21 U.S.C. 360bbb-3, to enable the utilization of medicines before approving. Ensuing regulative specialists expanded the scope of testing to which the medication or treatment has been submitted, as well as the class of drugs qualified for thought. The scope and relevance of EUAs are further governed by actual pioneer, which may change the significance of situations classified as general prosperity crises and within which the FDA might release EUAs Considering the COVID-19 flare-up, the HHS (Health and Human Services) Secretary articulated a general prosperity emergency on February 4, 2020, for the brand-new SARS-CoV-2 disorder these consequences in illness COVID-19. In response to the COVID-19 epidemic, the FDA granted EUAs in 2020 for remdesivir, enhanced blood, Fresenius Propoven 2 percent emulsion (propofol), and bamlanivimab. The FDA cancelled the Emergency use authorization (EUA) that drew in the exploratory monoclonal adjusting proficient medicine Bamlanivimab for use without assistance in the treatment of difficult-to-organize COVID-19 in grown-ups and positive pediatric victims on April 16, 2021.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Emergency Use Authorization for COVID-19 Vaccines and Practical Considerations for the Future ; day:05 ; month:10 ; year:2023
Journal of Health and Allied Sciences ; (05.10.2023)
- Beteiligte Personen und Organisationen
-
Monika, S.
R., Kruthika M.
P., Gowrav M.
V., Balamuralidhara
- DOI
-
10.1055/s-0043-1769904
- URN
-
urn:nbn:de:101:1-2023120710321663429812
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Monika, S.
- R., Kruthika M.
- P., Gowrav M.
- V., Balamuralidhara
Ähnliche Objekte (12)
Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications
Economic evaluation of meningococcal vaccines: considerations for the future
Authorization of the first COVID-19 emergency vaccines: The matters arising
Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches
Great authorization for Django, like Pyramid
Practical Considerations for Perforator Flap Thinning Procedures Revisited
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Extended Authorization Policy for Graph-Structured Data
Practical considerations for the use of mTOR inhibitors
Practical considerations of dietary therapies for epilepsy in adults
Devisenzuteilungsbestätigungen (Sub-Authorization)
Authorization - private welfare
Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications
Economic evaluation of meningococcal vaccines: considerations for the future
Authorization of the first COVID-19 emergency vaccines: The matters arising
Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches
Great authorization for Django, like Pyramid
Practical Considerations for Perforator Flap Thinning Procedures Revisited
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Extended Authorization Policy for Graph-Structured Data
Practical considerations for the use of mTOR inhibitors
Practical considerations of dietary therapies for epilepsy in adults
Devisenzuteilungsbestätigungen (Sub-Authorization)
Authorization - private welfare
Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications
Economic evaluation of meningococcal vaccines: considerations for the future
Authorization of the first COVID-19 emergency vaccines: The matters arising
Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches
Great authorization for Django, like Pyramid
Practical Considerations for Perforator Flap Thinning Procedures Revisited
Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Extended Authorization Policy for Graph-Structured Data
Practical considerations for the use of mTOR inhibitors
Practical considerations of dietary therapies for epilepsy in adults
Devisenzuteilungsbestätigungen (Sub-Authorization)